Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review

被引:13
作者
Bai, Jing [1 ]
Li, Dan [1 ]
Yang, Peidan [1 ]
Xu, Kunyan [1 ]
Wang, Yingnan [2 ]
Li, Qian [3 ]
Liu, Jiang [1 ]
Du, Wenli [1 ]
Zhang, Fengbin [2 ]
Feng, Rui [1 ]
机构
[1] Hebei Med Univ, Hosp 4, Dept Pharm, Shijiazhuang, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Gastroenterol, Shijiazhuang, Hebei, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Thorac Surg, Shijiazhuang, Hebei, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
关键词
camrelizumab; myocarditis; myositis; myasthenia gravis; immune-related adverse events; IMMUNE; EXACERBATION; IPILIMUMAB; NIVOLUMAB; ANTIBODY; MELANOMA; PATIENT;
D O I
10.3389/fonc.2021.778185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received anti-programmed cell death protein 1 (PD-1) (camrelizumab) therapy and the occurrence of sequential immune-related adverse events (irAEs). Although many irAEs have been reported, severe myositis caused by camrelizumab with simultaneous involvement of multiple organs, including the myocardium, respiratory muscles, and skeletal muscles, has rarely been described in literature. This 69-year-old male patient developed a grade 4 camrelizumab-induced adverse reaction according to the Common Terminology Criteria for Adverse Events (CTCAE) and was successfully treated with methylprednisolone and immunoglobulins. The early identification of irAEs, immediate discontinuation of immunotherapy, use of steroids and/or immunosuppressants, and adjuvant supportive treatment are critical to the clinical prognosis of patients. It should be aware that autoimmune complications can occur even when ICI treatment is ceased.
引用
收藏
页数:7
相关论文
共 31 条
[1]   PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].
Alsaab, Hashem O. ;
Sau, Samaresh ;
Alzhrani, Rami ;
Tatiparti, Katyayani ;
Bhise, Ketki ;
Kashaw, Sushil K. ;
Iyer, Arun K. .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[2]   Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].
Brahmer, Julie R. ;
Lacchetti, Christina ;
Schneider, Bryan J. ;
Atkins, Michael B. ;
Brassil, Kelly J. ;
Caterino, Jeffrey M. ;
Chau, Ian ;
Ernstoff, Marc S. ;
Gardner, Jennifer M. ;
Ginex, Pamela ;
Hallmeyer, Sigrun ;
Chakrabarty, Jennifer Holter ;
Leighl, Natasha B. ;
Mammen, Jennifer S. ;
McDermott, David F. ;
Naing, Aung ;
Nastoupil, Loretta J. ;
Phillips, Tanyanika ;
Porter, Laura D. ;
Puzanov, Igor ;
Reichner, Cristina A. ;
Santomasso, Bianca D. ;
Seigel, Carole ;
Spira, Alexander ;
Suarez-Almazor, Maria E. ;
Wang, Yinghong ;
Weber, Jeffrey S. ;
Wolchok, Jedd D. ;
Thompson, John A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+
[3]   Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210 [J].
Chen, Xuelian ;
Ma, Lanying ;
Wang, Xi ;
Mo, Hongnan ;
Wu, Dawei ;
Lan, Bo ;
Qu, Dong ;
Zhang, Hongtu ;
Huang, Jing ;
Xu, Binghe .
CANCER BIOLOGY & MEDICINE, 2019, 16 (01) :173-+
[4]   Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review [J].
Chen, Yukai ;
Jia, Yijun ;
Liu, Qinghua ;
Shen, Yunli ;
Zhu, Hui ;
Dong, Xue ;
Huang, Jianhao ;
Lu, Jingjing ;
Yin, Qi .
ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (07) :8512-8517
[5]   Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma [J].
Eggermont, Alexander M. M. ;
Blank, Christian U. ;
Mandala, Mario ;
Long, Georgina, V ;
Atkinson, Victoria ;
Dalle, Stephane ;
Haydon, Andrew ;
Lichinitser, Mikhail ;
Khattak, Adnan ;
Carlino, Matteo S. ;
Sandhu, Shahneen ;
Larkin, James ;
Puig, Susana ;
Ascierto, Paolo A. ;
Rutkowski, Piotr ;
Schadendorf, Dirk ;
Koornstra, Rutger ;
Hernandez-Aya, Leonel ;
Maio, Michele ;
van den Eertwegh, Alfonsus J. M. ;
Grob, Jean-Jacques ;
Gutzmer, Ralf ;
Jamal, Rahima ;
Lorigan, Paul ;
Ibrahim, Nageatte ;
Marreaud, Sandrine ;
van Akkooi, Alexander C. J. ;
Suciu, Stefan ;
Robert, Caroline .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1789-1801
[6]   Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy [J].
Esfahani, Khashayar ;
Buhlaiga, Najwa ;
Thebault, Pamela ;
Lapointe, Rejean ;
Johnson, Nathalie A. ;
Miller, Wilson H., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) :2375-2376
[7]   Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials [J].
Fang, Wenfeng ;
Yang, Yunpeng ;
Ma, Yuxiang ;
Hong, Shaodong ;
Lin, Lizhu ;
He, Xiaohui ;
Xiong, Jianping ;
Li, Ping ;
Zhao, Hongyun ;
Huang, Yan ;
Zhang, Yang ;
Chen, Likun ;
Zhou, Ningning ;
Zhao, Yuanyuan ;
Hou, Xue ;
Yang, Qing ;
Zhang, Li .
LANCET ONCOLOGY, 2018, 19 (10) :1338-1350
[8]   Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4 [J].
Goldstein, Barbara L. ;
Gedmintas, Lydia ;
Todd, Derrick J. .
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (03) :768-769
[9]   Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study [J].
Huang, Jing ;
Xu, Jianming ;
Chen, Yun ;
Zhuang, Wu ;
Zhang, Yiping ;
Chen, Zhendong ;
Chen, Jia ;
Zhang, Helong ;
Niu, Zuoxing ;
Fan, Qingxia ;
Lin, Lizhu ;
Gu, Kangsheng ;
Liu, Ying ;
Ba, Yi ;
Miao, Zhanhui ;
Jiang, Xiaodong ;
Zeng, Ming ;
Chen, Jianhua ;
Fu, Zhichao ;
Gan, Lu ;
Wang, Jun ;
Zhan, Xianbao ;
Liu, Tianshu ;
Li, Zhiping ;
Shen, Lin ;
Shu, Yongqian ;
Zhang, Tao ;
Yang, Qing ;
Zou, Jianjun .
LANCET ONCOLOGY, 2020, 21 (06) :832-842
[10]   Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma [J].
Huang, Jing ;
Xu, Binghe ;
Mo, Hongnan ;
Zhang, Weilong ;
Chen, Xuelian ;
Wu, Dawei ;
Qu, Dong ;
Wang, Xingyuan ;
Lan, Bo ;
Yang, Beibei ;
Wang, Pei ;
Zhang, Hongtu ;
Yang, Qing ;
Jiao, Yuchen .
CLINICAL CANCER RESEARCH, 2018, 24 (06) :1296-1304